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Psoriasiform pemphigus foliaceus: a
report of two cases
Pemphigus foliaceus (PF) represents an autoimmune blistering disease
characterized by the disruption of epidermal intercellular adhesion
proteins. Clinical findings include superficial crusted erosions in a
seborrheic distribution; however, the disease can rarely present as an
exfoliative erythroderma. Histopathologic findings include acantholysis
with cleavage within the granular layer. Direct immunofluorescence
studies show intercellular IgG and complement deposition. We present
two patients, to our dermatology department, with a previous diagnosis
of psoriasis, with an exfoliative erythroderma, which ultimately proved
to be because of PF based on histopathological features, direct
immunofluorescence results and levels of antibodies against
desmoglein 1. Both patients responded well to oral prednisone and
rituximab. This variant of PF should be entertained in both the clinical
differential diagnosis of psoriasiform erythroderma and in the
microscopic differential diagnosis of psoriasiform epidermal hyperplasia
with focal acantholysis, particularly in patients for whom the clinical
history is not classic for psoriasis or for whom conventional psoriasis
therapies have not proven beneficial.
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Pemphigus foliaceus (PF) is an autoimmune blistering
disease characterized by the disruption of epidermal
intercellular adhesion proteins, including the cad-
herin desmoglein (DSG) 1.1 As PF characteristically
manifests with superficial crusted erosions in a seb-
orrheic distribution, the disease can rarely present as
an exfoliative erythroderma.1
Herein, we present two patients with a previous
diagnosis of psoriasis who presented to our derma-
tology department with an exfoliative erythroderma,
which ultimately proved to be because of PF based
on histopathological features, direct immunofluores-
cence results and levels of antibodies against DSG 1.
Reports of cases
Patient 1
A 71-year-old African-American man with a history
notable for biopsy-proven psoriasis presented to
the Emergency Department with near-total body
erythroderma. He stated that his skin was flaring.
He complained of significant pruritus with scaling
and malodor. He also endorsed that he had recently
been taking mycophenolate mofetil, although he felt
this had worsened his skin condition and therefore
discontinued the medication.
The patient appeared well and was in no acute
distress. Examining his skin revealed a diffuse ery-
throderma with significant desquamation and scal-
ing, and superficial erosions of the palms bilaterally
(Fig. 1). The erythema and desquamation covered
90% of his total body surface area.
A punch biopsy revealed psoriasiform epider-
mal hyperplasia with mild spongiosis, papillomatosis,
hypergranulosis and confluent parakeratosis. Subtle
acantholysis was present focally within the gran-
ular layer of the epidermis (Fig. 2A,B). A super-
ficial perivascular infiltrate of lymphocytes with
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Fig. 1. Desquamation and scaling with superficial erosions involve
the hand.
many plasma cells, a few eosinophils and scat-
tered melanophages was observed in the dermis.
Direct immunofluorescence examination of the skin
biopsy specimen revealed intercellular space binding
of granular immunoglobulin g (IgG), focal granular
C3 and weak dermal epidermal junction (DEJ) bind-
ing of linear fibrin, consistent with the pemphigus
group (Fig. 3). A retrospective review of this patient’s
biopsy from 1996 revealed psoriasiform epidermal
hyperplasia, subcorneal neutrophils and a small focus
of superficial acantholysis (Fig. 4). Anti-DSG 1 IgG
was elevated to 228.6 (<14.0), while anti-DSG 3 IgG
was normal at 0.33 (<9.0).
The patient was started on oral prednisone 80 mg
daily, but he was unable to tolerate this dose due
to insomnia. Therefore, 1 week later his dose was
decreased to 60 mg daily. He received two infusions
of rituximab 2 weeks apart and showed significant
clinical improvement with almost complete clearing
of his erythroderma and healing of all areas of
desquamation (Fig. 5). At a follow-up appointment
2 weeks after discharge, the patient was satisfied with
his improvement and had no appreciable pruritus.
A slow taper of prednisone was initiated.
Fig. 3. A biopsy from left abdomen stained with anti-IgG revealed
intercellular space binding of granular IgG, consistent with
pemphigus (direct immunofluorescence).
Fig. 4. A biopsy from the same patient, obtained in 1996, showed
psoriasiform epidermal hyperplasia, subcorneal neutrophils and a
small focus of superficial acantholysis (hematoxylin/eosin).
Patient 2
A 74-year-old woman with a 3 to 4-year history of
psoriasis, confirmed with a biopsy performed by her
referring dermatologist, presented to our outpatient
A B
Fig. 2. (A and B) A biopsy from the left abdomen shows psoriasiform epidermal hyperplasia with subtle acantholysis present focally within the
granular layer of the epidermis (hematoxylin/eosin).
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Fig. 5. Status post two infusions of rituximab, 2 weeks apart, with
significant clinical improvement and almost complete healing of all
areas of desquamation.
Fig. 6. Near-confluent erythema on the upper arm with associated
thick, flake-like scale.
clinic with a brightly erythematous, painful, scaly
eruption involving her face, upper trunk, proximal
upper extremities and intertriginous folds. Prior to
her presentation, her psoriasis had been generally
well controlled with narrow band ultraviolet B
(UVB) phototherapy thrice a week. However,
recent treatment near home with broadband UVB
phototherapy failed to adequately control her disease.
At the time of her presentation, she complained of
significant erythema, pain and malodorous drainage.
The patient was a well-appearing woman in no
acute distress. A total body skin examination showed
near-confluent erythema on the face, chest and
upper arms with associated thick, flake-like scale
(Fig. 6). Macerated erythematous plaques with focal
erosions and foul-smelling drainage involved the
inframammary and crural folds and axillae.
A punch biopsy showed a small intracorneal
pustule with a split near the granular layer
and underlying superficial dermal inflammation
with neutrophils and eosinophils (Fig. 7A,B). Direct
A
B
Fig. 7. (A and B) A biopsy shows an intracorneal pustule with a
split near the granular layer and underlying superficial dermal
inflammation with neutrophils and eosinophils (hematoxylin/eosin).
Fig. 8. A biopsy stained with anti-human IgG shows intercellular
space deposition of IgG consistent with pemphigus (direct
immunofluorescence).
immunofluorescence examination of the biopsy
sample showed intercellular space deposition of IgG
consistent with the pemphigus group (Fig. 8). IgG
antibodies directed against DSG 1 was elevated to
221.0 (<14.0), while anti-DSG 3 IgG was normal at
1.2 (<9.0).
The patient was treated with prednisone at a
dose of 1 mg/kg in combination with mycopheno-
late mofetil, and topical steroids under occlusion,
resulting in rapid improvement of her skin disease.
However, several weeks thereafter, she developed
thrombocytopenia and acute bacterial cystitis with
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concern for pyelonephritis. Mycophenolate mofetil
was discontinued, and the patient was admitted to
the hospital for treatment of her bladder infection.
Her pemphigus subsequently flared, necessitating an
increase in her systemic corticosteroid dose. She
continued to flare each time her prednisone dose
was decreased, even with slow tapers. Ultimately,
the decision was made to initiate treatment with
intravenous immunoglobulin and rituximab. Follow-
ing the second rituximab infusion, her pemphigus
has remained well controlled, even with tapering of
corticosteroids.
Discussion
PF is an uncommon blistering disease. The incidence
of PF varies between populations and has been
described in all races. The prevalence of PF is
roughly equal between men and women, and the
onset of disease is most common in middle age.2
Clinical lesions consist of superficial crusted
erosions on an erythematous base, generally confined
to the seborrheic areas.2 PF may also present with
erythema and scaling localized to the scalp, and
this may mimic seborrheic dermatitis.3,4 Patients
often complain of pain, burning or pruritus. Unlike
patients with pemphigus vulgaris (PV), patients with
PF rarely develop mucosal lesions. The erosions may
become generalized, and occasionally an exfoliative
erythroderma may develop.5–10 PF presenting as
an exfoliative erythroderma has been reported
more frequently in the endemic form of PF, fogo
selvagem,1 although a case reported by Nousari et al.6
describes a patient with non-endemic erythrodermic
PF, ultimately proving to be fatal. This case
emphasizes the importance of obtaining a specimen
for direct immunoflourescence when examining
erythrodermic patients.6 In a review of 90 cases by
Pal et al.,8 PF was estimated to cause erythroderma
in approximately 6% of cases.
Histopathologic findings of PF include acantholy-
sis within the granular layer, and because of this, the
stratum corneummay be absent. Subcorneal pustules
may also be seen. The epidermis deep to the granular
layer is usually intact.5 Direct immunofluorescence
studies show intercellular IgG and complement
deposition.2
PF is characterized by IgG antibodies directed
against an epidermal desmosomal protein, specifi-
cally DSG 1.1 DSG 1 is a cadherin protein found at
the desmosomal cell junction. Binding of IgG anti-
bodies to DSG 1 causes acantholysis of keratinocytes
in and around the granular layer, where DSG 1
is primarily localized and is critical for cell-to-cell
adhesion.2 Unlike PV, mucosal surfaces are not
involved in PF becausemucousmembranes primarily
express DSG 3, a target in PV, but not PF.2
PF generally follows a chronic course, although
spontaneous resolutionmay occur. Prior to treatment
with glucocorticoids, PF was fatal in approximately
60% of patients.1 Therapy is aimed at halting
the production of pathogenic antibodies. Therapy
varies depending on the severity of disease,
but includes treatment with topical steroids for
localized disease. Patients with more widespread
involvement or erythroderma may be treated with
oral steroids in conjunction with various steroid-
sparing agents such as mycophenolate mofetil or
cyclophosphamide. Alternative treatment modalities
for patients resistant tomore conventional treatments
include rituximab, intravenous immunoglobulin or
plasmapheresis.5
Our two cases are interesting in that the patients
had a prior history of psoriasis that had become
unresponsive to conventional therapy, and ultimately
were diagnosed with PF. Very few patients with both
PF and psoriasis have been reported.11–14 A few the-
ories have been proposed to explain a potential link
between psoriasis and pemphigus. Tomasini et al.,13
suggested that antigenic stimulation could induce
abnormally high levels of IgG against keratinocytes,
leading to the development of a bullous disorder.
Another theory hypothesizes that inflammation from
other skin diseases could create a favorable environ-
ment for the expression of pemphigus antigens and
improve the activity of pathogenic autoantibodies.12
It has also been suggested that altered regulation of
T-cells with rising production of autoantibodies may
be a conceivable link between the clinical manifes-
tations of these two diseases in the same patient.12
Finally, plasminogen activation is known to play a
role in acantholysis, and elevated levels of plasmino-
gen activator have been showed in psoriatic lesions.11
In our cases, the patients had previous histopatho-
logic diagnoses of psoriasis and had been treated for
many years. Interestingly, in a retrospective review
of our first patient’s initial biopsy, psoriasiform epi-
dermal hyperplasia was noted, but with a small focus
of superficial acantholysis. It may be the case that
this patient did not in fact have psoriasis, but rather
only a psoriasiform variant of PF. This would explain
why this patient had been previously unresponsive
to conventional psoriasis treatments. In light of her
advanced age at the time of diagnosis, it is also possi-
ble that our second patient did not have psoriasis, but
rather a similar psoriasiform variant of PF. However,
this is speculative as the patient’s outside records
were not available for review, and she may indeed
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have had both psoriasis and PF concomitantly. We
believe it is also important to consider a diagnosis
of pityriasis rubra pilaris (PRP) when evaluating a
patient with generalized erythroderma. PRP can be
a difficult diagnosis to make histopathologically, as
the microscopic findings may not only be subtle,
but can also mimic other skin diseases. In addition,
subcorneal acantholysis has been reported in biopsies
from patients with PRP resembling PF.15,16
This rare variant of PF should be entertained in
the clinical differential diagnosis of erythroderma
or a diffuse papulosquamous eruption. It should
also be considered in the histopathologic differential
diagnosis of psoriasiform epidermal hyperplasia with
focal acantholysis, particularly in patients for whom
the clinical history is not classic for psoriasis, or
for whom conventional psoriasis therapies have not
proven beneficial.
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